Tarsus Added to NASDAQ Biotechnology Index
16 déc. 2022 07h00 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease
15 déc. 2022 08h30 HE
|
Tarsus Pharmaceuticals, Inc
Positive Phase 1b Callisto data shows that TP-05 is well tolerated and safety data supports progression to Phase 2a Phase 2a Carpo trial to evaluate the safety, tolerability, and proof-of-activity of...
Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements
09 nov. 2022 07h00 HE
|
Tarsus Pharmaceuticals, Inc
New Drug Application for TP-03 accepted; PDUFA target action date August 25, 2023 Launched disease education, field medical team and payor engagement in anticipation of TP-03 launch Cash runway...
Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting
25 oct. 2022 08h30 HE
|
Tarsus Pharmaceuticals, Inc
Saturn-2 follow-up data to be presented on TP-03 for the treatment of Demodex blepharitis Tarsus recently submitted NDA to the FDA for TP-03 Data from an investigator-initiated trial evaluating...
Tarsus Announces Transition Plans for Board of Directors
11 oct. 2022 08h30 HE
|
Tarsus Pharmaceuticals, Inc
Co-founder and Chairman Michael Ackermann plans to transition off Board of Directors Wendy Yarno will become Lead Independent Director and CEO Bobak Azamian will become Chairman upon Dr. Ackermann’s...
Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair
06 oct. 2022 08h30 HE
|
Tarsus Pharmaceuticals, Inc
Mr. Morrison brings over 40 years of financial and operational expertise in life sciences IRVINE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose...
Tarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis
29 sept. 2022 08h30 HE
|
Tarsus Pharmaceuticals, Inc
Demodex blepharitis is a highly prevalent, yet often missed or misdiagnosed lid margin disease that impacts approximately 25 million eye care patients in the U.S. IRVINE, Calif., Sept. 29, 2022 ...
Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings
27 sept. 2022 12h00 HE
|
Tarsus Pharmaceuticals, Inc
Positive data to be presented at WCC VIII and AAO 2022 conferences in Chicago Tarsus recently submitted NDA to the FDA for TP-03 IRVINE, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Tarsus...
Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitis
07 sept. 2022 07h00 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements
11 août 2022 16h05 HE
|
Tarsus Pharmaceuticals, Inc
TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial; NDA submission expected this year Initiated Ersa Phase 2a trial evaluating TP-03 for the treatment...